2024-03-19 18:23:47
Microsoft is expanding its collaboration with NVIDIA to bring the power of generative AI, cloud and accelerated computing to healthcare and life sciences organizations. The collaboration will bring together the global scale, security, and advanced computing capabilities of Microsoft Azure withNVIDIA DGX Cloudand the setNVIDIA Claraof computing platforms, software and services to help organizations in these sectors accelerate innovation and improve patient care. Leveraging the immense power of the cloud, cutting-edge AI, and advanced computing capabilities, the collaboration aims to accelerate clinical research and drug discovery, advance medical imaging-based diagnostic technology, and increase access to precision medicine.
“Microsoft is building on its long-standing collaboration with NVIDIA to empower the healthcare and life sciences industry with the power of Azure and generative AI, helping to unlock new horizons for clinical research, drug discovery and patient care in around the world,” said Peter Durlach, corporate vice president of Healthcare and Life Sciences at Microsoft.
“Through this collaboration, we aim to help the industry unlock advancements in healthcare, making care more accurate, accessible and effective to make a meaningful difference in the lives of patients globally.”
“The convergence of AI, cloud computing and healthcare is poised to transform patient care,” said Kimberly Powell, vice president of healthcare at NVIDIA. “Our collaboration with Microsoft will help unlock new possibilities and drive meaningful impact for patients around the world.”
The expanded collaboration will expand opportunities for healthcare providers, pharmaceutical and biotechnology companies. Medical device developers can now innovate faster in clinical research, drug discovery and care delivery. All with greater efficiency and effectiveness.
Faster drug discovery with NVIDIA BioNeMo on NVIDIA DGX Cloud, hosted on Microsoft Azure
Hosted on the NVIDIA DGX Cloud on Azure, theNVIDIA BioNeMooffers the fastest path to developing and deploying AI models, thereby accelerating the journey to AI-powered drug discovery. BioNeMo is a generative AI platform for drug discovery that simplifies and accelerates model training on proprietary data and scales model deployment for drug discovery applications. By analyzing vast data sets with unprecedented speed and accuracy, it can help scientists identify potential drug candidates more efficiently. The implications are profound: faster access to life-saving therapies for patients around the world.
Enhancing Clinical Research and Care Delivery with Image-Based AI Diagnostic Technology Leveraging Microsoft Azure, NVIDIA MONAI, and Nuance Precision Imaging Network
The combination of the power of Azure,NVIDIA MONAI (Medical Open Network for AI) e Nuance Precision Imaging Network(PIN) enables the safe and effective development, validation, deployment, and evaluation of medical imaging AI models at scale. With the combined offering, developers can create high-performance medical imaging AI models; healthcare providers can deploy a single PIN platform to run a wide range of third-party AI models integrated into clinical workflows; and clinical researchers can accelerate drug discovery. For example, theIA do Mass General Brighamleveraged MONAI and PIN in the followingmath of COVID-19 to support a federated approach with the aim of building models capable of assessing lung function and predicting oxygen needs for symptomatic patients.
Furthermore, theFlywheelis providing a highly optimized imaging data management application for data scientists, integrated with MONAI and powered by Azure AI, that improves the way medical imaging data is curated while significantly reducing the time required for image preparation. research data and training medical AI models.
Flywheel, NVIDIA and researchers atUniversity of Wisconsin School of Medicine and Public Healthare also working together to revolutionize medical imaging research through AI technology. The collaboration combines the UW–Madison team’s medical research insights, Flywheel’s imaging data platform, and NVIDIA MONAI microservices, all powered by Azure, to enable automated classifications of anatomical studies. The initiative has the potential to revolutionize medical image curation and significantly reduce the time required to prepare research data, representing a significant leap forward in enabling AI-driven medical advances.
“Our team at the UW School of Medicine and Public Health is focused on applying advanced technology to boost our research efforts and make it easier for our study teams to access large-scale data sets,” said John Garrett, Ph.D. ., assistant professor of radiology and medical physics and director of imaging informatics at UW-Madison. “Through this initiative, we can leverage advanced methods and platforms and tools from Flywheel and NVIDIA to scale our data curation process, allowing us to spend more time on research projects and training AI models.”
Accelerating genomic analysis with SOPHiA DDMTMPlatform on Microsoft Azure powered by NVIDIA Parabricks
Microsoft, NVIDIA e SOPHiA GENETICSare collaborating to leverage this partnership’s expertise in technology and genomics to develop a streamlined whole genome analytical solution that is scalable and comprehensive. As part of this collaboration, the SOPHiA DDM Software-as-a-Service platform, hosted on Azure, will be powered byNVIDIA Parabricksfor the SOPHiA DDM Whole Genome Application. Parabricks is a scalable genomic analysis software package that leverages full-stack accelerated computing to process entire genomes in minutes. Compatible with all major sequencing instruments, Parabricks supports diverse bioinformatics workflows and integrates AI for accuracy and customization. SOPHiA GENETICS will also use powerful NVIDIA GPUs on Azure to process computationally heavy workloads, providing a scalable and efficient solution.
“At SOPHiA GENETICS, we offer a universal, cloud-based platform — the SOPHiA DDM™ Platform — that enables healthcare institutions to gain fast, robust, and actionable insights from their data. Our technology analyzes genomic data, along with other modalities, to provide collective intelligence for institutions around the world to support discoveries, treatment decisions and drug development efforts, benefiting patients with cancer and rare inherited genetic diseases. By leveraging Azure and NVIDIA technology capabilities, we will be able to scale our superior analytical performance, short turnaround time, and cost-effective solutions to encompass the entire genome, further expanding our ability to benefit our customers and their patients,” said Abhimanyu Verma, technology director at SOPHiA GENETICS.
Azure AI: Democratizing AI for healthcare professionals
Microsoft is collaborating with NVIDIA to make a future set of NVIDIA healthcare microservices available on Azure AI for optimized inference and fine-tuning. Once available, researchers, clinicians, and developers can explore these next-generation models and deploy them as endpoints in the Azure AI Model Catalog. Azure AI democratizes AI adoption for users in healthcare, from radiologists tuning an AI algorithm to geneticists deciphering complex variants, while driving innovation and redefining patient care through collaboration across disciplines.
Microsoft aims to propel healthcare and life sciences into an exciting new era of medicine, helping to unlock transformative possibilities for patients around the world. Combining the global scale, security, and advanced computing capabilities of Microsoft Azure with NVIDIA DGX Cloud and the NVIDIA Clara suite is poised to accelerate advances in clinical research, drug discovery, and care delivery.
About Microsoft
Microsoft (Nasdaq “MSFT” @microsoft)’s mission is to empower every person and every organization on the planet to achieve more. Present in 190 countries and with 122 subsidiaries around the world, Microsoft celebrates 35 years in Brazil in 2024. The company offers its solutions and its ability to create innovative products and services to boost the country’s economic development. To expand the impact of the company’s long-term partnership with Brazil, the Microsoft Mais Brasil Plan was launched in 2020, whose actions are organized into four pillars: Supporting Inclusive Economic Growth, Protection of Fundamental Rights, Enabling a Sustainable Future and Trust in Technology. With Mais Brasil, on the inclusive economic growth front alone, Microsoft has already reached around 12.5 million people (started a course) between October 2020 and January 2024, and another 2.8 million people completed at least a course. More information at: Microsoft Mais Brasil – Impact Report in Brazil
1710901386
#Microsoft #announces #collaboration #NVIDIA #accelerate #innovation #healthcare #life #sciences #Microsoft #Azure
